Incyte Corporation share price logo

Incyte Corporation Share Price

NASDAQ: INCY

Large Cap

$96.56

+0.34

(+0.35%)

Live

as on

Incyte Corporation Stock Performance

as on April 23, 2026 at 5:07 am IST

  • Day's Low

    Day's High

    $96.49
    $98.19
    downward going graph

    0.07%

    Downside

    1.69%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $56.77
    $112.29
    downward going graph

    41.21%

    Downside

    16.29%

    Upside

    downward going graph

Incyte Corporation share price movements today

Previous Close
$96.22
Open
$97.33
Volume
516.9K
Day's Low - High
$96.49 - $98.19
52 Week Low - High
$56.77 - $112.29

Incyte Corporation Historical Returns

1 Month Return
+ 5.99 %
3 Month Return
-8.41 %
1 Year Return
+ 67.69 %
3 Year Return
+ 29 %
5 Year Return
+ 14.3 %

Incyte Corporation Stock Fundamentals & Key Indicators

Check Incyte Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$19.1B

EPS (TTM)

7.3751

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.44%

PE Ratio (TTM)

15.01

Industry PE ratio

-9.801875

PEG Ratio

0.3507

EBITDA

1.4B

Revenue (TTM)

5.1B

Profit Margin

25.03%

Return On Equity TTM

29.87%

Incyte Corporation Stock Valuation

Track how Incyte Corporation P/E has moved over time to understand its valuation trends.

Incyte Corporation in the last 5 years

  • Overview

  • Trends

Lowest (13.04x)

September 30, 2025

Industry (-9.80x)

April 22, 2026

Today (15.01x)

April 22, 2026

Highest (151.83x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 15.01x

Incyte Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Incyte Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$19.1B14.3%15.0125.03%
BUY$41.2B123.87%131.818.45%
BUY$111.1B102.14%28.532.94%
NA$36.5BNA128.255.37%
BUY$79.2B52.39%18.0531.41%

Stock Returns calculator for Incyte Corporation Stock including INR - Dollar returns

The Incyte Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Incyte Corporation investment value today

Current value as on today

₹1,85,262

Returns

₹85,262

(+85.26%)

Returns from Incyte Corporation Stock

₹68,282 (+68.28%)

Dollar Impact

₹16,980 (+16.98%)

Analyst Recommendation on Incyte Corporation Stock

Based on 29 analysts

BUY

55.17%

Buy

44.83%

Hold

0.00%

Sell

Based on 29 analysts, 55.17% of analysts recommend a 'BUY' rating for Incyte Corporation. Average target price of $107.36

Incyte Corporation Share Price Target

Get share price movements and forecasts by analysts on Incyte Corporation.

What analysts predicted

10.06%UPSIDE

Target Price

$107.36

Current Price

$96.56

Analyzed by

29 Analysts

Target

$107.36

Incyte Corporation target price $107.36, a slight upside of 10.06% compared to current price of $96.56. According to 29 analysts rating.

Incyte Corporation Stock’s Investor Sentiment and Interest

Search interest for Incyte Corporation Stock has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-6% versus previous 30 day period

Incyte Corporation Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
919
1,013
880
1,043
1,137
1,178
1,052
1,215
1,365
1,506
Gross Profit
843
927
803
950
1,035
1,073
963
1,119
1,266
1,369
Operating Income
215
205
90
-477
169
297
216
310
443
383
EBITDA
255
293
258
-367
179
336
257
581
506
414
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
21
21
21
22
22
22
22
22
24
23
Income Before Tax
233
270
236
-389
156
313
234
558
482
389
Income Tax Expense
62
69
66
54
50
112
75
153
58
90
Net Income
171
201
169
-444
106
201
158
404
424
299
Net Profit Margin
18.64%
19.84%
19.25%
-42.60%
9.36%
17.07%
15.03%
33.32%
31.05%
19.86%

Incyte Corporation Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,105
1,536
1,881
2,158
2,666
2,986
3,394
3,695
4,241
5,141
Gross Profit
1,001
1,426
1,754
2,011
2,505
2,798
3,141
3,380
3,863
4,702
Operating Income
164
-235
155
421
-240
637
599
651
80
1,342
EBITDA
204
-253
171
543
-178
630
599
919
408
1,760
Interest Expense
38
6
1
1
2
1
2
2
2
2
Depreciation
-
52
54
54
51
57
67
79
89
93
Income Before Tax
107
-312
115
486
-232
570
529
834
316
1,664
Income Tax Expense
3
0
5
39
63
-378
188
236
284
377
Net Income
104
-313
109
446
-295
948
340
597
32
1,286
Net Profit Margin
9.43%
-20.38%
5.82%
20.70%
-11.09%
31.76%
10.04%
16.17%
0.77%
25.03%

Incyte Corporation Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
201
169
-444
106
201
158
404
424
299
Operating Cash Flow
147
218
-575
310
381
266
44
559
543
Investing Cash Flow
-154
-73
213
38
-21
1
-18
-47
-37
Financing Cash Flow
0
-12
-1,997
-32
20
-12
-11
-12
137
Change in Cash
-13
132
-2,358
316
383
253
13
500
642

Incyte Corporation Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-313
109
446
-295
948
340
597
32
1,286
Operating Cash Flow
-92
336
710
-124
749
969
496
335
1,413
Investing Cash Flow
-349
-86
-87
-269
-207
-78
-207
157
-102
Financing Cash Flow
690
14
45
71
6
0
-20
-2,021
101
Change in Cash
247
264
668
-318
544
893
262
-1,525
1,410

Mutual Funds that own Incyte Corporation Stock

Check out the Mutual Funds with significant holdings in Incyte Corporation.

Funds
Holdings
Shares Held
Motilal Oswal S&P 500 Index Fund Direct Growth
Motilal Oswal S&P 500 Index Fund Direct Growth
0.02803%
1248

Global Institutional Holdings in Incyte Corporation

Funds
Holdings
Los Angeles Capital Management LLC
1.15%
Northern Trust Corp
0.87%
Los Angeles Capital Management LLC
0.88%
AQR Capital Management LLC
3.98%
State Street Corp
4.86%

Incyte Corporation News & Key Events

  • img

    Today's Timeline - 10 February

    Tue, 08:00 PM

    -

    Incyte reports Q4 revenue of $1.51 billion, exceeding estimates, but EPS of $1.80 misses consensus by 7.06%.

Insights on Incyte Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, INCY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, INCY stock has moved up by 67.7%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.05B → 1.50B (in $), with an average increase of 11.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 47.4% return, outperforming this stock by 18.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 424.16M → 299.27M (in $), with an average decrease of 29.4% per quarter

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
OrganisationIncyte Corporation
Headquarters1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
IndustryBiotechnology
CEOMr. William J. Meury
E-voting on sharesClick here to vote

Key Management of Incyte Corporation

Name

Title

Dr. Steven H. Stein M.D.

Executive VP, Head of Late-stage Development & Chief Medical Officer

Mr. William J. Meury

CEO & Director

Ms. Alexis Smith

Vice President & Head of Investor Relations

Ms. Soni K. Basi Ph.D.

Executive VP & Chief Human Resources Officer

Mr. James H. Lee M.D., Ph.D.

Group VP, Head of Inflammation & AutoImmunity Group

Dr. Pablo J. Cagnoni M.D., Ph.D.

President and Global Head of Research & Development

Mr. Thomas Tray

Principal Financial Officer, VP of Finance & Chief Accounting Officer

Mr. Michael James Morrissey

Executive VP & Head of Global Technical Operations

Mr. Richard A. Hoffman J.D., M.B.A.

Executive VP & General Counsel

Ms. Pamela M. Murphy

Vice President of Investor Relations & Corporate Communications

FAQs

What is Incyte Corporation share price today?

Incyte Corporation share price today is $96.56 as on . Incyte Corporation share today touched a day high of $98.19 and a low of $96.49.

What is the 52 week high and 52 week low for Incyte Corporation share?

Incyte Corporation share touched a 52 week high of $112.29 on and a 52 week low of $56.77 on . Incyte Corporation stock price today i.e. is trending at $96.56,which is 14.01% down from its 52 week high and 70.09% up from its 52 week low.

What is Incyte Corporation's market capitalisation today?

Incyte Corporation market capitalisation is $0.02T as on .

How to invest in Incyte Corporation Stock (INCY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Incyte Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Incyte Corporation Shares that will get you 0.0155 shares as per Incyte Corporation share price of $96.56 per share as on April 22, 2026 at 11:37 pm IST.

What is the minimum amount required to buy Incyte Corporation Stock (INCY) from India?

Indian investors can start investing in Incyte Corporation (INCY) shares with as little as ₹93.775 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.75 in Incyte Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on Incyte Corporation share’s latest price of $96.56 as on April 22, 2026 at 11:37 pm IST, you will get 0.1036 shares of Incyte Corporation. Learn more about fractional shares .

What are the returns that Incyte Corporation has given to Indian investors in the last 5 years?

Incyte Corporation stock has given 14.3% share price returns and 23.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?